You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Targeting PAR1: Now What?
|
|---|---|
| Published in |
Trends in Pharmacological Sciences, May 2017
|
| DOI | 10.1016/j.tips.2017.05.001 |
| Pubmed ID | |
| Authors |
Robert Flaumenhaft, Karen De Ceunynck |
| Abstract |
Protease-activated receptors (PARs) are a ubiquitously expressed class of G-protein-coupled receptors (GPCRs) that enable cells to respond to proteases in the extracellular environment in a nuanced and dynamic manner. PAR1 is the archetypal family member and has been the object of large-scale drug development programs since the 1990s. Vorapaxar and drotrecogin-alfa are approved PAR1-targeted therapeutics, but safety concerns have limited the clinical use of vorapaxar and questions regarding the efficacy of drotrecogin-alfa led to its withdrawal from the market. New understanding of mechanisms of PAR1 function, discovery of improved strategies for modifying PAR1 function, and identification of novel indications for PAR1 modulators have provided new opportunities for therapies targeting PAR1. In this review, we critically evaluate prospects for the next generation of PAR1-targeted therapeutics. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Scientists | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 21% |
| Student > Ph. D. Student | 12 | 17% |
| Student > Master | 12 | 17% |
| Student > Doctoral Student | 6 | 8% |
| Researcher | 6 | 8% |
| Other | 7 | 10% |
| Unknown | 14 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 18 | 25% |
| Agricultural and Biological Sciences | 9 | 13% |
| Medicine and Dentistry | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Neuroscience | 4 | 6% |
| Other | 8 | 11% |
| Unknown | 20 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2022.
All research outputs
#2,010,701
of 25,382,440 outputs
Outputs from Trends in Pharmacological Sciences
#169
of 2,406 outputs
Outputs of similar age
#37,399
of 327,499 outputs
Outputs of similar age from Trends in Pharmacological Sciences
#4
of 22 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,406 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,499 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.